
Sign up to save your podcasts
Or


At the 2023 American Society of Clinical Oncology Annual Meeting, Dr. Slamon presented results from the NATALEE trial, showing that Kisqali plus an aromatase inhibitor after surgery for early-stage, hormone receptor-positive, HER2-negative breast cancer, reduced recurrence risk by 25% compared to an aromatase inhibitor alone.
Listen to the podcast to hear Dr. Slamon explain:
By Breastcancer.org4.3
4242 ratings
At the 2023 American Society of Clinical Oncology Annual Meeting, Dr. Slamon presented results from the NATALEE trial, showing that Kisqali plus an aromatase inhibitor after surgery for early-stage, hormone receptor-positive, HER2-negative breast cancer, reduced recurrence risk by 25% compared to an aromatase inhibitor alone.
Listen to the podcast to hear Dr. Slamon explain:

21,982 Listeners

1,112 Listeners

2,033 Listeners

1,693 Listeners

2,632 Listeners

3,501 Listeners

9,274 Listeners

53 Listeners

4,500 Listeners

328 Listeners

385 Listeners

20,203 Listeners

1,183 Listeners

122 Listeners

30 Listeners